• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Packaging Technology

    Elemental Impurities: The Time Has Come

    Continuous vs. Batch Production

    2018: The evolution of pharmaceutical packaging

    Formulation Development Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Sterling Pharma Invests £6M To Expand Offerings

    Bioclinica Announces Key Hires & Promotion

    PhoenixMD, STA Enter Manufacturing Agreement

    ProBioGen, Tizona Therapeutics Enter Collaboration

    Mayne Pharma Opens $80M Oral Solid Dose Facility
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Arcinova Receives £1.5M Innovate UK Grant

    Vetter Announces Visit from Illinois Governor

    Sterling Pharma Invests £6M To Expand Offerings

    PhoenixMD, STA Enter Manufacturing Agreement

    Mayne Pharma Opens $80M Oral Solid Dose Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    INTERPHEX: Adents Showcases Cloud-Based Serialization Solution

    Almac Group Expands Packaging Capabilities

    Catalent Bolsters Clinical Supply Capabilities

    West, Stevanato Group Enter Ompi EZ-fill Alliance

    Pharmaceutical Packaging Technology
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Sterling Pharma Invests £6M To Expand Offerings

    PhoenixMD, STA Enter Manufacturing Agreement

    ProBioGen, Tizona Therapeutics Enter Collaboration

    INTERPHEX: Adents Showcases Cloud-Based Serialization Solution

    SAMDI Tech Enters Drug Discovery Collaboration
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Blockchain: The Next Big Trend in BioPharma?

    Emergent Completes Market Authorization

    Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle: ICH Q12

    LSNE Expands Capabilities and QC Laboratory Space

    Evotec Launches Drug Development Service
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    IQVIA

    Avista Pharma Solutions

    Adaptive Clinical Systems

    Exelead

    Fusion Scientific Laboratories
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers Q&A: Nancy Gillett of Charles River Laboratories

    Managing preclinical operations

    Related CONTENT
    • The Wild West of Basic Discovery
    • Quality Metrics & CDMOs
    • Financial Report: Charles River Laboratories
    • The Good, the Bad, and the Donald
    • Whither Washington?
    Gil Y. Roth06.06.11
    Nancy A. Gillett, D.V.M., Ph.D., is the corporate executive vice president and president, Global Preclinical Services, at Charles River Laboratories. In her role, Dr. Gillett drives the strategy for the company's global preclinical business operations. We conducted an e-mail exchange to discuss CRL's views on the biopharma marketplace.  —GYR

    Contract Pharma: What does the marketplace look like through the eyes of a CRO?

    Nancy Gillett: With next year’s patent expirations on the horizon, we are seeing continuous shifts within the pharma and biotech marketplace. Pharma is going through a constant process of looking inward at their infrastructure, determining what has to be done internally and what can be done externally as we continue to see big clients redefine themselves.

    As part of that continuous self-examination process, pharma is looking closely at price, changing and re-changing their infrastructures and scrutinizing their pipelines. Some of the large drug companies have begun to outsource work that was historically not available. We anticipate that, over time, there will be more companies following suit in order to compete effectively, particularly since the patent cliff looms in the next year.

    It’s a fact that our client base is undergoing significant change and their efforts to create a new more efficient drug development model will involve increased outsourcing. The ability to utilize CRO expertise and infrastructure instead of investing in their own will enable them to redeploy assets to more productive initiatives and to replenish their drug development pipelines with therapies to advance human health.

    CP: How are the marketplace dynamics impacting CROs and Charles River?

    NG: Our clients want it all — superior scientific expertise, accelerated timelines, and quality — at a competitive price. We understand their price sensitivity and are working with clients so they can benefit from our high-quality and scientific expertise at a competitive price.

    We are continuously evaluating our portfolio of products and services to ensure it meets the evolving needs of our customers. In addition, we’ll continue to identify opportunities to work with clients more effectively both to advance their processes and at the same time drive our growth.

    CP: What do the pharma/biopharma industry’s transformations look like from a CRO’s perspective?

    NG: We are seeing more and more clients evaluate their core competencies and partner with CROs to provide the expertise they do not have internally. This is creating a model where CROs are now considered an extension of their clients’ team.

    CP: What are the growth drivers for the industry and how is CRL positioning itself in these areas?

    NG: We are seeing an increased interest from our clients for support with their biosimilar development. In addition, we are also seeing increased interest in the area of biobetters, which are new molecules that are derived from an existing biologic product but have been deliberately modified to improve stability, efficacy or safety.

    Companies are considering the potential return on investment required to bring a biosimilar to market and, in many instances, are not finding the numbers to their liking. Biobetters allow them to target an established mechanism, safety and efficacy profile but gain the benefit of sales of a new molecular entity. The costs are the same as developing a new biological product, but the chances of successful registration are significantly higher.

    We are supporting our clients by developing testing programs for originator biological products and are using this experience to help biobetter developers tailor their testing to their product. We have developed product-specific testing programs for biosimilars where regulatory guidance is available, but recognize the complexities of new and better biological products and provide guidance for maximizing the regulatory impact of the studies performed.

    In addition, a specific area of increased demand is in our cell-based and stem cell services. Our clients rely on us for stem cell therapy guidance and regulatory support in this growing area of drug discovery. To meet client demand, we were the first CRO to start a Cell Product Toxicology Program. The Program is staffed with experts in animal research models, molecular biology, veterinary pathology, immunology, regulation and pharmacology. We were also the first CRO to form a Stem Cells Research Oversight committee (S-CRO), an institution-wide review board that oversees the ethical conduct of cell therapy research — this is a requirement for running cell research funded by California (CIRM) and a number of other states.

    CP: In your opinion, who and what are driving innovation in the industry?

    NG: As an industry we are continuously looking for the best ideas and sources of innovation. Big pharma continues to be a source of innovation and also fueling innovation throughout the industry. As part of a growing trend, big pharma is providing funding to the academic market, which is a future source of innovation. We are also seeing big pharma fund some of the innovation in biotech as well.

    CP: What do you think accounts for the (relative) failure of large-scale R&D models?

    NG: I don’t believe failure is the right word. We are targeting very complex disease areas, such as cardiovascular, CNS, inflammation and oncology, which require very complex treatments using combination therapies. The drug development process is very complex.

    Gil Roth has been the editor of Contract Pharma since its debut in 1999. He can be reached at gil@rodpub.com.
    Related Searches
    • Testing
    • Development
    • Biopharma
    • CRO
    Suggested For You
    So You Think You Know  All About Excipients? So You Think You Know All About Excipients?
    CROs & Next-Gen  Drug Development CROs & Next-Gen Drug Development
    Overcoming Preclinical Drug Development Hurdles Overcoming Preclinical Drug Development Hurdles
    Aseptic Manufacturing Trends Roundtable Aseptic Manufacturing Trends Roundtable
     Vantage Consulting is First Systems Integrator to Join PBOA Vantage Consulting is First Systems Integrator to Join PBOA
    Nimbus Therapeutics, Charles River in Strategic R&D Alliance Nimbus Therapeutics, Charles River in Strategic R&D Alliance
    Charles River Launches Oncology Research Model Charles River Launches Oncology Research Model
    Reality and Un-Reality:  Continuous Processing in Pharmaceutical Manufacturing Reality and Un-Reality: Continuous Processing in Pharmaceutical Manufacturing
    DCAT Week DCAT Week '17 Q&A: API Market Trends
    Charles River, Chiesi Extend Drug Discovery Alliance Charles River, Chiesi Extend Drug Discovery Alliance
    Whither Washington? Whither Washington?
    The Good, the Bad, and the Donald The Good, the Bad, and the Donald
    Financial Report: Charles River Laboratories Financial Report: Charles River Laboratories
    Quality Metrics & CDMOs Quality Metrics & CDMOs
    The Wild West of Basic Discovery The Wild West of Basic Discovery

    Related Features

    • Contract BioManufacturing in China: Creating a New Segment

      Contract BioManufacturing in China: Creating a New Segment

      An up-close look at China’s growing market for CMO services.
      Vicky Qing Xia and Leo Cai Yang, BioPlan Associates 04.10.18

    • Integrated Early-Stage Drug Development and Manufacturing

      Integrated Early-Stage Drug Development and Manufacturing

      A key to accelerating the drug development process.
      Mark Egerton, Chief Executive Officer, Quotient Sciences 03.09.18

    • CEO Spotlight: Sterling Pharma Solutions

      CEO Spotlight: Sterling Pharma Solutions

      A conversation with Kevin Cook about CDMO-sponsor partnerships and outsourcing
      Tim Wright, Editor, Contract Pharma 11.07.17


    • The Challenges of Drug Development

      The Challenges of Drug Development

      As recorded in two new worthwhile books
      Michael A. Martorelli, Fairmount Partners 10.11.17

    • Making Medicines: Speeding the Path from Idea to Patient

      Making Medicines: Speeding the Path from Idea to Patient

      Speeding the path from idea to patient
      Dan Bowles and Michael Tracey, Cambrex 10.11.17

    • How Can We Predict Immunogenicity Earlier in Drug Discovery?

      How Can We Predict Immunogenicity Earlier in Drug Discovery?

      Identifying potential immune responses earlier in the development of biotherapeutics.
      Kevin Merlo and Tim Moran, Dassault Systèmes Biovia 09.01.17


    • cGMP Manufacture
      Biopharmaceutical Contract Manufacturing Market

      Biopharmaceutical Contract Manufacturing Market

      The market continues to grow, projected to exceed $4 billion in 2017
      William Downey, President, HighTech Business Decisions 06.06.17

    • In vivo Models Targeting Respiratory Diseases

      In vivo Models Targeting Respiratory Diseases

      Insight into methods of optimizing in vivo efficacy studies and what developments might be coming to fruition in the future
      Steve Jordan, Principal Scientist, In vivo Respiratory Discovery, Envigo 05.09.17

    • Formulating Candidates  with Bioavailability Issues

      Formulating Candidates with Bioavailability Issues

      To avoid the solubility pitfalls that too often halt a medicines progress from clinic to market, it’s vital to start formulat
      Stephen Tindal, Director - Science and Technology, Catalent 05.09.17


    • The Challenges in Developing Therapeutic Cannabis

      The Challenges in Developing Therapeutic Cannabis

      While holding much promise, cannabis-based drug therapies are complex and their development offers many challenges to overcom
      Dr. David Fulper, Director, Technology Support, Catalent 04.03.17

    • Formulation Strategies for  Aging Consumers

      Formulation Strategies for Aging Consumers

      Convenience, flavor and novel combinations of ingredients can help offer better product experiences.
      Stephen Tindal, Director, Science and Technology, Catalent Pharma Solutions 03.07.17

    • Precision Medicine

      Precision Medicine

      An overview of healthcare’s new wave and future hope
      Kiley R. Prilliman, TRI 03.07.17

    • Know Your Drug:  A Solution to Dissolution

      Know Your Drug: A Solution to Dissolution

      Examining key strategies for solubility and dissolution assessment of new drug products, drug product intermediates and APIs
      Luís Sousa, Mafalda Paiva and Pedro Serôdio, Hovione 03.07.17

    • Modeling & Simulation for  Drug Development & Formulation

      Modeling & Simulation for Drug Development & Formulation

      A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.
      Nathan Teuscher and Nikunjkumar Patel , Certara 03.07.17

    • CROs and Today’s  R&D Landscape

      CROs and Today’s R&D Landscape

      John Lewis of ACRO discusses opportunities, challenges, and the future CRO
      Kristin Brooks, Associate Editor, Contract Pharma 11.09.16

    Breaking News
    • Sterling Pharma Invests £6M To Expand Offerings
    • AGC Chemicals to Feature Advanced Intermediates
    • Avema to Showcase Range of Services
    • Peter Stein to Deliver FDA Keynote Presentation
    • CPhI NA Conference to Focus on Fostering Innovation
    View Breaking News >
    CURRENT ISSUE

    April 2018

    • Pharmaceutical Packaging Technology
    • Elemental Impurities: The Time Has Come
    • Continuous vs. Batch Production
    • 2018: The evolution of pharmaceutical packaging
    • Formulation Development Trends
    • Changing Dynamics: The CDMO market in focus
    • Contract BioManufacturing in China: Creating a New Segment
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.